Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study

T. Karampitsakos (Athens, Greece), G. Gomatou (Athens, Greece), V. Tzilas (Athens, Greece), E. Bouros (Athens, Greece), E. Markozannes (Athens, Greece), E. Manali (Athens, Greece), I. Tomos (Athens, Greece), K. Antoniou (Heraklion, Greece), A. Trachalaki (Heraklion, Greece), L. Kolilekas (Athens, Greece), I. Korbila (Athens, Greece), P. Tomos (Athens, Greece), S. Chrysikos (Athens, Greece), K. Dimakou (Athens, Greece), K. Loverdos (Athens, Greece), A. Gaga (Athens, Greece), Z. Daniil (Larissa, Greece), F. Bardaka (Larissa, Greece), I. Papanikolaou (Corfu, Greece), D. Papakosta (Thessaloniki, Greece), K. Markopoulou (Thessaloniki, Greece), R. Tringidou (Athens, Greece), S. Papiris (Athens, Greece), D. Bouros (Athens, Greece), A. Tzouvelekis (Athens, Greece)

Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Session: Comorbidities of idiopathic pulmonary fibrosis
Session type: Thematic Poster
Number: 1311
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Karampitsakos (Athens, Greece), G. Gomatou (Athens, Greece), V. Tzilas (Athens, Greece), E. Bouros (Athens, Greece), E. Markozannes (Athens, Greece), E. Manali (Athens, Greece), I. Tomos (Athens, Greece), K. Antoniou (Heraklion, Greece), A. Trachalaki (Heraklion, Greece), L. Kolilekas (Athens, Greece), I. Korbila (Athens, Greece), P. Tomos (Athens, Greece), S. Chrysikos (Athens, Greece), K. Dimakou (Athens, Greece), K. Loverdos (Athens, Greece), A. Gaga (Athens, Greece), Z. Daniil (Larissa, Greece), F. Bardaka (Larissa, Greece), I. Papanikolaou (Corfu, Greece), D. Papakosta (Thessaloniki, Greece), K. Markopoulou (Thessaloniki, Greece), R. Tringidou (Athens, Greece), S. Papiris (Athens, Greece), D. Bouros (Athens, Greece), A. Tzouvelekis (Athens, Greece). Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study. 1311

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Europe.
Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis
Year: 2021



Prevalence of cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study
Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias
Year: 2018

Treatment dilemmas in sarcoidosis - a retrospective cohort study
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013

Incidence and prevalence of Systemic Sclerosis-associated Interstitial Lung Disease in a multicenter prospective cohort study.
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020


PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting
Source: International Congress 2014 – ILDs 6
Year: 2014


Is pulmonary sarcoidosis more severe in children? A multicentric retrospective study
Source: International Congress 2014 – Sarcoidosis
Year: 2014


Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study
Source: International Congress 2014 – ILDs 6
Year: 2014

Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


Idiopathic Pulmonary Fibrosis based on disease behavior: Workshop summary of a Japanese multicenter study
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019

Nintedanib in Idiopathic Pulmonary Fibrosis: a single-centre real-life experience
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017

Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients
Source: International Congress 2014 – Sarcoidosis
Year: 2014

Lung cancer in combined pulmonary fibrosis and emphysema: a large retrospective cohort analysis
Source: ERJ Open Res, 6 (4) 00521-2020; 10.1183/23120541.00521-2020
Year: 2020



Pulmonary scar carcinomas: A two-year retrospective observational study
Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer
Year: 2013


Bosentan does not improve outcome in patients with steroid-resistant pulmonary sarcoidosis – Results from a double-blind placebo-controlled phase 2 trial
Source: International Congress 2014 – Sarcoidosis
Year: 2014

Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


Comorbidities associated with sarcoidosis – Results from long-term observational study
Source: International Congress 2014 – Sarcoidosis
Year: 2014

A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 6
Year: 2014


Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial
Source: International Congress 2014 – ILDs 3
Year: 2014


Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study
Source: ERJ Open Res, 8 (1) 00443-2021; 10.1183/23120541.00443-2021
Year: 2022